Hainan Haishen Tongzhou Pharmaceutical Co., Ltd.

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome and inhibiting RNA-dependent protein synthesis.

This product belongs to the azole antifungal drug, with a wide antifungal spectrum. Oral and intravenous administration of this product is effective against fungal infections in humans and various animals, such as Candida infection, Cryptococcus neoformans infection, Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, F. fischeri, Mycosporium carinii, etc. The mechanism of action of this product is mainly to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor, blocking the transfer RNA (t-RNA) from binding to the site, and also blocking the transfer of the polypeptide chain from the acceptor site to the site, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor, blocking the transfer RNA (t-RNA) from binding to the site, and also blocking the transfer of the polypeptide chain from the acceptor site to the site, thereby inhibiting bacterial protein synthesis.